Workflow
Standard BioTools(LAB)
icon
Search documents
Standard BioTools(LAB) - 2021 Q4 - Annual Report
2022-03-08 00:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ (Exact name of registrant as specified in its charter) Delaware 77-0513190 State or other jurisdiction of incorporation or organization I.R.S. Employer Identification No. 2 Tower Place, Suite 2000 South San Francisco, CA 94080 Address of principal executive offices Zip Code FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal yea ...
Fluidigm (FLDM) Investor Presentation - Slideshow
2022-03-04 22:01
Investor Overview February 2022 Legal Information Forward-looking statements This presentation and the accompanying presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Fluidigm's vision and strategy, target markets and revenues, anticipated collaborations, growth plans, recurring revenue streams, expense management, product applications and adoption in certain markets, addressable market gro ...
Standard BioTools(LAB) - 2021 Q3 - Earnings Call Presentation
2021-11-09 19:27
Investor Overview November 2021 Legal Information Forward-looking statements This presentation and the accompanying presentations (including an oral presentation) contain forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding: advantages of and prospects for Fluidigm's technologies and products; market opportunities and growth and Fluidigm access to and participation in such markets; revenue growth and profitability ...
Standard BioTools(LAB) - 2021 Q3 - Earnings Call Transcript
2021-11-09 03:18
Fluidigm Corporation (FLDM) Q3 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants Chris Linthwaite – CEO Peter Denardo – IR Vikram Jog – CFO Conference Call Participants Operator Good afternoon and thank you for standing by. Welcome to the Fluidigm Third Quarter 2021 Financial Results conference call. At this time all participants are in a listen-only mode. After the speakers presentation there will be a question-and-answer session. [Operator Instructions]. I would now like to hand th ...
Standard BioTools(LAB) - 2021 Q3 - Quarterly Report
2021-11-09 01:23
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _____________________________________________ Commission file number: 001-34180 FLUIDIGM CORPORATION (Exact name ...
Fluidigm (FLDM) Investor Presentation - Slideshow
2021-10-01 19:40
Investor Overview September 2021 Legal Information Forward-looking statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding revenue growth and profitability targets, consumables and services recurring revenue growth expectations, market opportunities, expense management, productivity and efficiency goals, product innovation, Fluidigm's access ...
Standard BioTools(LAB) - 2021 Q2 - Earnings Call Presentation
2021-08-09 17:57
Supplemental Financial Information Q2 2021 August 5, 2021 Legal Information Forward-looking statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding revenue growth and profitability targets, consumables and services recurring revenue growth expectations, market opportunities, expense management, productivity and efficiency goals, product inno ...
Standard BioTools(LAB) - 2021 Q2 - Quarterly Report
2021-08-06 20:24
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 2 Tower Place, Ste 2000 South San Francisco, CA 94080 Address of principal executive offices Zip Code Registrant's telephone number, including area code: (650) 266-6000 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...
Standard BioTools(LAB) - 2021 Q1 - Earnings Call Transcript
2021-05-09 20:30
Fluidigm Corporation (FLDM) Q1 2021 Earnings Conference Call May 6, 2021 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Chris Linthwaite - President and Chief Executive Officer Vikram Jog - Chief Financial Officer Conference Call Participants Dan Brennan - UBS Sung Ji Nam - BTIG LLC Operator Good day and thank you for standing by. Welcome to the Fluidigm First Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' pre ...
Standard BioTools(LAB) - 2021 Q1 - Earnings Call Presentation
2021-05-07 23:03
Investor Overview May 6, 2021 Legal Information Forward-looking statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding revenue growth and profitability targets, consumables and services recurring revenue growth expectations, market opportunities, expense management, productivity and efficiency goals, product innovation, Fluidigm's access to ...